Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Syndax Pharma (NQ: SNDX ) 18.98 +0.12 (+0.64%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Syndax Pharma Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) August 14, 2024 From Incyte and Syndax Pharmaceuticals Via Business Wire Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors August 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies June 17, 2024 EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END Via FinancialNewsMedia Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies June 17, 2024 From FN Media Group LLC Via GlobeNewswire Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger June 10, 2024 From Pyxis Oncology Via GlobeNewswire Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease December 10, 2023 From Incyte and Syndax Pharmaceuticals Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
